Literature DB >> 24790727

Update on the therapy of Behçet disease.

Zeinab Saleh1, Thurayya Arayssi2.   

Abstract

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

Entities:  

Keywords:  Behçet disease; Behçet syndrome; biologic therapy; therapy; treatment; tumor necrosis factor α

Year:  2014        PMID: 24790727      PMCID: PMC3992825          DOI: 10.1177/2040622314523062

Source DB:  PubMed          Journal:  Ther Adv Chronic Dis        ISSN: 2040-6223            Impact factor:   5.091


  194 in total

1.  [Behçet's disease - Infliximab in the treatment of mucocutaneous manifestations].

Authors:  Sara Lestre; Felicidade Trindade; Andrea Martins; Juliana Baptista; Ana Barata Feio; Maria João Paiva Lopes
Journal:  Acta Reumatol Port       Date:  2009 Oct-Dec       Impact factor: 1.290

2.  Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.

Authors:  Hiroshi Keino; Annabelle A Okada; Takayo Watanabe; Wakako Taki
Journal:  Br J Ophthalmol       Date:  2010-12-22       Impact factor: 4.638

3.  EULAR recommendations for the management of Behçet disease.

Authors:  G Hatemi; A Silman; D Bang; B Bodaghi; A M Chamberlain; A Gul; M H Houman; I Kötter; I Olivieri; C Salvarani; P P Sfikakis; A Siva; M R Stanford; N Stübiger; S Yurdakul; H Yazici
Journal:  Ann Rheum Dis       Date:  2008-01-31       Impact factor: 19.103

4.  Cyclosporin A is effective, but not safe, in the management of Behçet's disease.

Authors:  B Wechsler; E B Mertani; P le Hoang; F de Groc; J C Piette; H Beaufils; B Aupetit; H le Minh; J Rottembourg
Journal:  Arthritis Rheum       Date:  1986-04

5.  Low dose cyclosporin-A therapy in Behçet's disease.

Authors:  H Sajjadi; M Soheilian; H Ahmadieh; K Hassanein; M Parvin; M Azarmina; V Ehyaee; B Amiransari
Journal:  J Ocul Pharmacol       Date:  1994

6.  Interleukin-1β-regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behcet's disease: an open-label pilot study.

Authors:  Ahmet Gül; Ilknur Tugal-Tutkun; Charles A Dinarello; Leonid Reznikov; Bahar Artim Esen; Amer Mirza; Patrick Scannon; Alan Solinger
Journal:  Ann Rheum Dis       Date:  2011-11-14       Impact factor: 19.103

7.  Colchicine versus placebo in Behçet's disease: randomized, double-blind, controlled crossover trial.

Authors:  Fereydoun Davatchi; Bahar Sadeghi Abdollahi; Arash Tehrani Banihashemi; Farhad Shahram; Abdolhadi Nadji; Hormoz Shams; Cheyda Chams-Davatchi
Journal:  Mod Rheumatol       Date:  2009-07-14       Impact factor: 3.023

Review 8.  The use of interferon alpha in Behçet disease: review of the literature.

Authors:  Ina Kötter; Ilhan Günaydin; Manfred Zierhut; Nicole Stübiger
Journal:  Semin Arthritis Rheum       Date:  2004-04       Impact factor: 5.532

9.  Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Behçet disease.

Authors:  Yukiko Yamada; Sunao Sugita; Hiroyuki Tanaka; Koju Kamoi; Tatsushi Kawaguchi; Manabu Mochizuki
Journal:  Br J Ophthalmol       Date:  2009-08-18       Impact factor: 4.638

10.  Inefficacy of azapropazone in the acute arthritis of Behçet's syndrome: a randomized, double blind, placebo controlled study.

Authors:  F Moral; V Hamuryudan; S Yurdakul; H Yazici
Journal:  Clin Exp Rheumatol       Date:  1995 Jul-Aug       Impact factor: 4.473

View more
  30 in total

1.  Budd-Chiari Syndrome in Behçet's Disease successfully managed with immunosuppressive and anticoagulant therapy: A case report and literature review.

Authors:  Christian Mario Amodeo Oblitas; Francisco Galeano-Valle; Neera Toledo-Samaniego; Blanca Pinilla-Llorente; Jorge Del Toro-Cervera; Arturo Álvarez-Luque; Alejandra García-García; Pablo Demelo-Rodriguez
Journal:  Intractable Rare Dis Res       Date:  2019-02

Review 2.  Gastrointestinal Behçet's disease: a review.

Authors:  Wasseem Skef; Matthew J Hamilton; Thurayya Arayssi
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

3.  A missed Behçet's case presenting with spontaneous epidural hematoma.

Authors:  Levent Karataş; Gönen Mengi; Özden Özyemişçi-Taşkıran
Journal:  Eur J Rheumatol       Date:  2015-06-24

Review 4.  Conditions presenting with symptoms of peripheral arterial disease.

Authors:  Aditya M Sharma; Patrick T Norton; Daisy Zhu
Journal:  Semin Intervent Radiol       Date:  2014-12       Impact factor: 1.513

5.  Urgent Surgical Management of Deep Femoral Artery Aneurysm in a Patient with Pre-Vasculo-Behcet Status.

Authors:  Tetsuya Sato; Harunobu Matsumoto; Naoyuki Kimura; Homore Okamura; Koichi Adachi; Koichi Yuri; Atsushi Yamaguchi; Shigeki Yamada; Hideo Adachi
Journal:  Ann Vasc Dis       Date:  2015-05-26

6.  Lessons of the month 2: A case of Behçet's disease: 70% have ophthalmic involvement.

Authors:  Ishna Auluck; Ayesha Karimi; Simon Taylor
Journal:  Clin Med (Lond)       Date:  2019-11       Impact factor: 2.659

7.  mRNA Expression Level of Interleukin Genes in the Determining Phases of Behçet's Disease.

Authors:  Serpil Taheri; Murat Borlu; Cem Evereklioglu; Sevda Yesim Ozdemir; Yusuf Ozkul
Journal:  Ann Dermatol       Date:  2015-05-29       Impact factor: 1.444

8.  The Effectiveness of Intraocular Methotrexate in the Treatment of Posterior Uveitis in Behçet's Disease Patients Compared to Retrobulbar Steroids Injection.

Authors:  Hossam El Din Mohamed Khalil; Heba A El Gendy; Hala Ahmed Raafat Youssef; Hazem Effat Haroun; Tamer Atef Gheita; Hossam Mahmoud Bakir
Journal:  J Ophthalmol       Date:  2016-12-13       Impact factor: 1.909

9.  Mandibular bone mineral density in patients with Behçet's disease.

Authors:  Fatih Asutay; Yusuf Atalay; Ahmet Hüseyin Acar; Hilal Asutay; Selma Eroğlu; Muammer Çağrı Burdurlu
Journal:  Ther Clin Risk Manag       Date:  2015-10-14       Impact factor: 2.423

Review 10.  Spontaneous Intra-Abdominal Hemorrhage Due to Rupture of Jejunal Artery Aneurysm in Behcet Disease: Case Report and Literature Review.

Authors:  Xiao-Yan Wu; Jiang-Peng Wei; Xiu-Yuan Zhao; Yue Wang; Huan-Huan Wu; Tao Shi; Tong Liu; Gang Liu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.